Keywords: lilly, almita, enters, ph, iii, trial, sclc

Lilly's Almita enters Ph III trial for SCLC

Article | 30 October 2006

Print This

US drugmaker Eli Lilly says that it has initiated a Phase III trial of its anticancer agent Alimta (pemetrexed for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in